An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Clinical Trial ID NCT01619774

Rank	Title	Journal	Year	PubWeight™‹?›
1	MEK and the inhibitors: from bench to bedside.	J Hematol Oncol	2013	1.90
2	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.	Oncotarget	2014	1.33
3	The MAPK pathway across different malignancies: a new perspective.	Cancer	2014	1.22
4	Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.	Pigment Cell Melanoma Res	2013	1.13
5	Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.	Mol Cancer Ther	2014	0.92
6	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.	Front Oncol	2013	0.89
7	New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.	Drug Healthc Patient Saf	2014	0.77
8	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.	JAMA Oncol	2016	0.75